FibroBiologics Files 8-K for Equity Sale
Ticker: FBLG · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1958777
| Field | Detail |
|---|---|
| Company | Fibrobiologics, INC. (FBLG) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $451 thousand, $4.09, $3,436 thousand, $3,887 thousand |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities, 8-k
Related Tickers: FBIO
TL;DR
FibroBiologics sold unregistered equity, check the details.
AI Summary
FibroBiologics, Inc. announced on August 26, 2024, the unregistered sale of equity securities. The company filed an 8-K report detailing this event, which also included Regulation FD disclosures and financial statements. Specific details regarding the number of shares sold or the price per share were not immediately available in the provided text.
Why It Matters
This filing indicates FibroBiologics has issued new equity, which could impact existing shareholders through dilution or signal the company's need for capital.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes indicate less favorable terms or a need for immediate capital, and the lack of specific details in the initial report warrants caution.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- August 26, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41934 (filing_id) — SEC File Number
- 86-3329066 (tax_id) — I.R.S. Employer Identification Number
- 455 E. Medical Center Blvd. Suite 300 Houston, Texas 77598 (address) — Principal executive offices
- (281) 671-5150 (phone_number) — Registrant's telephone number
FAQ
What type of equity securities were sold?
The filing indicates an 'Unregistered Sales of Equity Securities' but does not specify the type of securities in the provided text.
How many shares were sold in this unregistered offering?
The provided text does not specify the number of shares sold.
What was the price per share for the unregistered equity sale?
The price per share for the unregistered equity sale is not detailed in the provided text.
What is the purpose of this unregistered sale of equity securities?
The purpose of the unregistered sale of equity securities is not explicitly stated in the provided text, though 8-K filings often relate to capital raising or other significant corporate events.
When was the unregistered sale of equity securities completed?
The earliest event reported is August 26, 2024, which is the date of the report.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-27 16:01:28
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Market
- $451 thousand — ing in gross proceeds to the Company of $451 thousand. The sale of the Shares was exempt from
- $4.09 — 840,000 shares issued at a net price of $4.09 per share after applying the 10% discou
- $3,436 thousand — Company for cancellation, and remitted $3,436 thousand in gross proceeds to the Company. Sub
- $3,887 thousand — as received aggregate gross proceeds of $3,887 thousand from the sale of its securities to GEM
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-034006.txt ( ) — 211KB
- fblg-20240826.xsd (EX-101.SCH) — 3KB
- fblg-20240826_lab.xml (EX-101.LAB) — 33KB
- fblg-20240826_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 27, 2024 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer